Last reviewed · How we verify
Interferon Beta Therapy
At a glance
| Generic name | Interferon Beta Therapy |
|---|---|
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies (PHASE3)
- A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial (PHASE2)
- Pharmacogenomics of Drug Safety in Multiple Sclerosis
- Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC) (PHASE3)
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (PHASE3)
- Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis (PHASE3)
- Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Interferon Beta Therapy CI brief — competitive landscape report
- Interferon Beta Therapy updates RSS · CI watch RSS
- Biogen portfolio CI